InspireMD Inc. (NSPR)
NSPR Stock Price Chart
Key Info
| Market Cap | 14.52M |
| Revenue (ttm) | 3.34M |
| Net Income (ttm) | -9.25M |
| Shares Out | 34.88M |
| EPS (ttm) | -0.65 |
| PE Ratio | n/a |
| Forward PE | 11.70 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | December 4 |
| Last Price | $0.389 |
| Previous Close | $0.387 |
| Change ($) | 0.001 |
| Change (%) | 0.36% |
| Day's Open | 0.395 |
| Day's Range | 0.380 - 0.407 |
| Day's Volume | 1,255,062 |
| 52-Week Range | 0.294 - 1.410 |
NSPR Stock News
InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q3 2020 Results - Earnings Call Transcript
TEL AVIV, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke...
TEL AVIV, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke...
Earnings conference call to be held Monday, November 9, 2020 at 8:30 a.m. ET Earnings conference call to be held Monday, November 9, 2020 at 8:30 a.m. ET
TEL AVIV, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by c...
TEL AVIV, Israel, Oct. 06, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke...
Advancing the CARENET-III study of CGuard System for Stroke Prevention in the United States Advancing the CARENET-III study of CGuard System for Stroke Prevention in the United States
IDE Approval to Pave the Way for Pivotal Study of CGuard System for Carotid Artery Disease and Stroke Prevention in the United States IDE Approval to Pave the Way for Pivotal Study of CGuard S...
TEL AVIV, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused b...
TEL AVIV, Israel, Aug. 25, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
TEL AVIV, Israel, Aug. 10, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD's (NSPR) CEO Marvin Slosman on Q2 2020 Results - Earnings Call Transcript
In the second quarter the Company was granted approval to market its CGuard™ MicroNet stent in Brazil and completed an $11.5 million capital raise; reported outstanding results in studies t...
Conference Call to be held Wednesday, August 5, 2020 at 8:30am ET Conference Call to be held Wednesday, August 5, 2020 at 8:30am ET
Conference Call to be held Thursday, August 5, 2020 at 8:30am ET Conference Call to be held Thursday, August 5, 2020 at 8:30am ET
In a head-to-head evaluation, significantly fewer silent brain infarcts were associated with CGuard™ EPS versus Acculink™ at 30 days post-procedure In a head-to-head evaluation, significantly ...
Results indicate that 12 months after carotid intervention the CGuard EPS MicroNET-covered stent delivers sustained protection against postprocedural neurologic events
TEL AVIV, Israel, June 08, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by...
TEL AVIV, Israel, June 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by...
InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q1 2020 Results - Earnings Call Transcript
First quarter revenue growth driven by continued strong uptake of the CGuard™ Embolic Prevention System (EPS) in the company’s major markets
InspireMD's (NSPR) CEO Marvin Slosman on Q4 2019 Results - Earnings Call Transcript
Case demonstrates ease-of-use and exceptional patient safety features of CGuard™ EPS Case demonstrates ease-of-use and exceptional patient safety features of CGuard™ EPS
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
InspireMD, Inc. (NSPR) CEO Jim Barry on Q3 2019 Results - Earnings Call Transcript
TEL AVIV, Israel, Sept. 19, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused b...
TEL AVIV, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused b...
TEL AVIV, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by ca...
InspireMD, Inc. (NSPR) CEO Jim Barry on Q2 2019 Results - Earnings Call Transcript
InspireMD (NSPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
InspireMD, Inc. (NSPR) CEO Jim Barry on Q1 2019 Results - Earnings Call Transcript
About NSPR
InspireMD, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard... [Read more...]
| Industry Medical Devices | |
| CEO Marvin Slosman | Employees 48 |
| Stock Exchange NYSE American | Ticker Symbol NSPR |
Financial Performance
In 2019, InspireMD's revenue was $3.72 million, an increase of 3.33% compared to the previous year's $3.60 million. Losses were -$10.04 million, 38.7% more than in 2018.